Author: Sahara Makoto Takahashi Toshiyuki Imai Yasushi Nakajima Toshiaki Yao Atsushi Morita Toshihiro Hirata Yasunobu Nagai Ryozo
Publisher: Springer Publishing Company
ISSN: 0920-3206
Source: Cardiovascular Drugs and Therapy, Vol.20, Iss.5, 2006-10, pp. : 377-386
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Recent advances in our understanding of the pathophysiological and molecular mechanisms involved in pulmonary arterial hypertension have led to the development of novel and rational pharmacological therapies. In addition to conventional therapy (i.e., supplemental oxygen and calcium channel blockers), prostacyclin or endothelin receptor antagonists have been recommended as a first-line therapy for pulmonary arterial hypertension. However, these treatments have potential limitations with regard to their long-term efficacy and improvement in survival. Furthermore, intravenous prostacyclin (epoprostenol) therapy, which is recommended by most experts for patients with New York Heart Association (NYHA) functional class IV, is complicated, uncomfortable for patients, and expensive because of the cumbersome administration system. Considering these circumstances, it is necessary to develop additional novel therapeutic approaches that target the various components of this multifactorial disease.In this short review, we present an overview of the current treatment options for pulmonary arterial hypertension and describe a case report with primary pulmonary hypertension. A male patient with NYHA functional class IV and showing no response to calcium channel blockers and prostacyclin exhibited significantly improved exercise tolerance and hemodynamics and long-term survival for more than 2.5 years after receiving an oral combination therapy of a phosphodiesterase type 5 inhibitor (sildenafil), phosphodiesterase type 3 inhibitor (pimobendan), and nicorandil.We also discuss the background and plausible potential mechanisms involved in this case, as well as future perspectives in the treatment of pulmonary arterial hypertension.
Related content
Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design, Vol. 19, Iss. 22, 2013-07 ,pp. :
Targeted Oral Therapies in the Treatment of Pulmonary Arterial Hypertension
Clinical Drug Investigation, Vol. 30, Iss. 12, 2010-12 ,pp. :
Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
By O'Callaghan Dermot S Savale Laurent Yaïïci Azzedine Natali Delphine Jaïïs Xavier Parent Florence Montani David Humbert Marc Simonneau Géérald Sitbon Olivier
Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. :